Citations

Clear

623 citation(s) found for "Torres, V".

Considerations With Regard to the Relationship Between Anticoagulant Intake and Glaucoma Prognosis in Eyes With Optic Disc Hemorrhages
Rocha, Janaina A.G. , Carvalho, Carolina Rodrigues de, Scoralick, Ana Luiza Bassoli , Dias, Diego Torres , Prata, Tiago S.

Mayo Clinic

Journal of Glaucoma | April 27, 2019 | Volume: 28 | Issue: 7 | Pages: e133-e133

10.1097/ijg.0000000000001265 | PMID 30994487 Get It

Interim analysis of a phase I study of INCB040093, a PI3Kδ inhibitor, alone or in combination with INCB039110, a selective JAK1 inhibitor, in patients (pts) with relapsed or refractory (r/r) B-cell malignancies.
Forero‐Torres, Andres , Sher, Taimur , Scherle, Peggy , Schaub, Richard, Zhou, Li , Pulini, Jennifer, Leopold, Lance, Spear, Matthew A. , Phillips, Tycel , Diefenbach, Catherine , Talpaz, Moshe , Barr, Paul M.

Mayo Clinic

Journal of Clinical Oncology | April 22, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 8520-8520

10.1200/jco.2015.33.15_suppl.8520 Get It

A phase 1 study of INCB040093, a PI3Kδ inhibitor, alone or in combination with INCB039110, a selective JAK1 inhibitor: Interim results from patients (pts) with relapsed or refractory (r/r) classical Hodgkin lymphoma (cHL).
Forero‐Torres, Andres , Sher, Taimur , Schaub, Richard, Zhou, Li , Pulini, Jennifer, Leopold, Lance, Spear, Matthew A. , Barr, Paul M. , Diefenbach, Catherine , Talpaz, Moshe , Phillips, Tycel

Mayo Clinic

Journal of Clinical Oncology | April 19, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 8558-8558

10.1200/jco.2015.33.15_suppl.8558 Get It

A phase 2 trial of INCB040093 alone or in combination with INCB039110 in patients (pts) with relapsed or refractory (r/r) classical Hodgkin lymphoma (cHL).
Sher, Taimur , Lebovic, Daniel, Zhou, Li , Pulini, Jennifer, Spear, Matthew A. , Forero‐Torres, Andres , Barr, Paul M. , Phillips, Tycel

Mayo Clinic

Journal of Clinical Oncology | April 19, 2019 | Volume: 33 | Issue: 15_suppl | Pages: TPS8607-TPS8607

10.1200/jco.2015.33.15_suppl.tps8607 Get It

Incidence and Mortality of Renal Cell Carcinoma after Kidney Transplantation: A Meta-Analysis
Chewcharat, Api , Thongprayoon, Charat, Cheungpasitporn, Wisit , Aeddula, Narothama Reddy , Kaewput, Wisit , Watthanasuntorn, Kanramon , Lertjitbanjong, Ploypin , Sharma, Konika , Torres-Ortiz, Aldo, Leeaphorn, Napat, Khoury, Nadeen , Cheungpasitporn, Wisit , Aeddula, Narothama Reddy , Kaewput, Wisit , Chewcharat, Api , Khoury, Nadeen , Thongprayoon, Charat , Boonpheng, Boonphiphop , Torres-Ortiz, Aldo, Mao, Michael A.

Mayo Clinic

Journal of Clinical Medicine | April 17, 2019 | Volume: 8 | Issue: 4 | Pages: 530

10.3390/jcm8040530 | PMID 30999706 Get It

Background: The incidence and mortality of renal cell carcinoma (RCC) after kidney transplantation (KTx) remain unclear. This study’s aims were (1) to investigate the pooled incidence/incidence trends, and (2) to assess the mortality/mortality trends in KTx patients with RCC. Methods: A literature search was conducted using the MEDLINE, EMBASE and Cochrane databases from inception through October 2018. Studies that reported the incidence or mortality of RCC among kidney transplant recipients were included. The pooled incidence and 95% CI were calculated using a random-effect model. The protocol for this meta-analysis is registered with PROSPERO; no. CRD42018108994. Results: A total of 22 observational studies with a total of 320,190 KTx patients were enrolled. Overall, the pooled estimated incidence of RCC after KTx was 0.7% (95% CI: 0.5–0.8%, I2 = 93%). While the pooled estimated incidence of de novo RCC in the native kidney was 0.7% (95% CI: 0.6–0.9%, I2 = 88%), the pooled estimated incidence of RCC in the allograft kidney was 0.2% (95% CI: 0.1–0.4%, I2 = 64%). The pooled estimated mortality rate in KTx recipients with RCC was 15.0% (95% CI: 7.4–28.1%, I2 = 80%) at a mean follow-up time of 42 months after RCC diagnosis. While meta-regression analysis showed a significant negative correlation between year of study and incidence of de novo RCC post-KTx (slopes = −0.05, p = 0.01), there were no significant correlations between the year of study and mortality of patients with RCC (p = 0.50). Egger’s regression asymmetry test was performed and showed no publication bias in all analyses. Conclusions: The overall estimated incidence of RCC after KTX was 0.7%. Although there has been a potential decrease in the incidence of RCC post-KTx, mortality in KTx patients with RCC has not decreased over time.
Integrated Transcriptomic and Proteomic Analysis of Primary Human Umbilical Vein Endothelial Cells
Madugundu, Anil K. , Na, Chan Hyun , Nirujogi, Raja Sekhar , Renuse, Santosh , Kim, Kwang Pyo , Wilks, Christopher , Langmead, Ben , Collado‐Torres, Leonardo , Kim, Min‐Sik , Pandey, Akhilesh , Kim, Min-Sik , Pandey, Akhilesh , Pandey, Akhilesh , Kim, Kwang Pyo , Burns, Kathleen H , Ellis, Shannon , Halushka, Marc K.

Mayo Clinic

PROTEOMICS | April 15, 2019 | Volume: 19 | Issue: 15 | Pages: No page available

10.1002/pmic.201800315 | PMID 30983154 Get It

Abstract Understanding the molecular profile of every human cell type is essential for understanding its role in normal physiology and disease. Technological advancements in DNA sequencing, mass spectrometry, and computational methods allow us to carry out multiomics analyses although such approaches are not routine yet. Human umbilical vein endothelial cells (HUVECs) are a widely used model system to study pathological and physiological processes associated with the cardiovascular system. In this study, next‐generation sequencing and high‐resolution mass spectrometry to profile the transcriptome and proteome of primary HUVECs is employed. Analysis of 145 million paired‐end reads from next‐generation sequencing confirmed expression of 12 186 protein‐coding genes (FPKM ≥0.1), 439 novel long non‐coding RNAs, and revealed 6089 novel isoforms that were not annotated in GENCODE. Proteomics analysis identifies 6477 proteins including confirmation of N ‐termini for 1091 proteins, isoforms for 149 proteins, and 1034 phosphosites. A database search to specifically identify other post‐translational modifications provide evidence for a number of modification sites on 117 proteins which include ubiquitylation, lysine acetylation, and mono‐, di‐ and tri‐methylation events. Evidence for 11 “missing proteins,” which are proteins for which there was insufficient or no protein level evidence, is provided. Peptides supporting missing protein and novel events are validated by comparison of MS/MS fragmentation patterns with synthetic peptides. Finally, 245 variant peptides derived from 207 expressed proteins in addition to alternate translational start sites for seven proteins and evidence for novel proteoforms for five proteins resulting from alternative splicing are identified. Overall, it is believed that the integrated approach employed in this study is widely applicable to study any primary cell type for deeper molecular characterization.
Rate and impact of venous thromboembolism in patients with ST-segment elevation myocardial infarction: Analysis of the Nationwide Inpatient Sample database 2003–2013
Al‐Ogaili, Ahmed , Ayoub, Ali , Quintero, Luis Diaz , Torres, Christian , Fuentes, Harry E , Fugar, Setri , Kolkailah, Ahmed A. , Dakkak, Wael, Tafur, Alfonso , Yadav, Neha , Quintero, Luis D , Fuentes, Harry E

Mayo Clinic

Vascular Medicine | March 27, 2019 | Volume: 24 | Issue: 4 | Pages: 341-348

10.1177/1358863x19833451 | PMID 30915913 Get It

Venous thromboembolism (VTE) and coronary artery disease are major health issues that cause substantial morbidity and mortality. New data have emerged suggesting that these two conditions could have a close relationship. Thus, we sought to determine the trends in annual rate of VTE occurrence in patients with ST-segment elevation myocardial infarction (STEMI) and measure its impact on in-hospital mortality, bleeding complications, and cost and length of hospitalization. We queried the 2003–2013 Nationwide Inpatient Sample databases to identify adults with primary diagnosis of STEMI. VTE events were then allocated. Inpatient outcomes of patients with VTE were compared to those without VTE. Out of 2,495,757 hospitalizations for STEMI, VTE was diagnosed in 25,149 (1%) hospitalizations. Patients who experienced VTE were older (mean age: 67.5 vs 64.8, p < 0.01) and had a higher proportion of black patients (10.1% vs 7.7%, p < 0.001) and females (40.1% vs 35%, p < 0.001) compared to patients without VTE. There was an increasing trend in the rate of VTE during the study period (2003: 0.8% vs 2013: 1.0%, p < 0.001). Patients with VTE had a prolonged hospitalization (median: 9 vs 3 days, p < 0.001), increased cost, higher risk of gastrointestinal bleeding (OR: 2.13, p < 0.001), intracranial hemorrhage (OR: 2.14, p < 0.001), blood transfusions (OR: 1.94, p < 0.001), and mortality (OR: 1.39, p < 0.001). The rate of VTE occurrence in patients with STEMI in our study was 10 per 1000 admissions. VTE was associated with more bleeding complications, longer hospital stays, higher costs, and mortality. These findings suggest that a more aggressive approach for VTE prophylaxis may be warranted in this population.
Clinicopathological, immunophenotypic and genetic studies of mediastinal paragangliomas†
Hsu, Ying-Han R, Torres‐Mora, Jorge , Kipp, Benjamin R. , Sukov, William R. , Jenkins, Sarah M. , Voss, Jesse S. , Cassivi, Stephen D. , Roden, Anja C. , Barr Fritcher, Emily G, Hsu, Ying-Han R. , Fritcher, Emily G. Barr , Schaff, Hartzell V.

Mayo Clinic

European Journal of Cardio-Thoracic Surgery | March 21, 2019 | Volume: 56 | Issue: 5 | Pages: 867-875

10.1093/ejcts/ezz115 | PMID 31329844 Get It

Abstract OBJECTIVES Paragangliomas have unique features in the mediastinum, in part due to their location. Because of their paucity, they have not been thoroughly investigated. We studied the clinical, pathological, immunohistochemical and molecular features of mediastinal paragangliomas. METHODS Immunohistochemistry, next-generation sequencing mutation panel and the Oncoscan assay were performed. RESULTS Twenty-four patients with mediastinal paraganglioma (7 men, 29.2%) had a median age of 45.5 years (19.8–72.2). Twenty-one (87.5%) paragangliomas were completely resected. Six (of 24, 25.0%) tumours were considered metastatic. Mitotic activity occurred in 11 (of 24, 45.8%) paragangliomas. Programmed death-ligand 1 (PD-L1) (n = 23) was expressed in 6 (26%) patients in 10% (n = 2) and 1% (n = 4) of tumour cells, respectively. SDHB expression was lost in 19 (of 22, 86.4%) cases. ATRX expression was lost in 11 (of 23, 47.8%) cases. Next-generation sequencing revealed a single pathogenic mutation in 10 (of 19) specimens including SDHB (n = 4), SDHD (n = 6), SDHC (n = 1), ATRX (n = 1), and ≥2 mutations in 2 cases [SDHC and TERT (n = 1); SDHB, ATRX and TP53 (n = 1)]. Germline mutation analysis revealed the same succinate dehydrogenase mutation (or lack thereof) as identified in the paraganglioma in 11 (of 12) cases. During a median follow-up (n = 21) of 4.8 years (0.8–14.9), 3 patients developed metastases; 4 patients died, at least 1 of disease. CONCLUSIONS Mediastinal paragangliomas can be associated with morbidity and mortality. Many mediastinal paragangliomas have been reported to be associated with syndromes such as multiple endocrine neoplasia, von Hippel-Lindau or succinate dehydrogenase syndrome with mutation profiles dominated by alterations in genes associated with these syndromes.
Critical Care Echocardiography—Embracing the Future Today
Hernandez-Torres, Vivian , Prada, Gabriel , Díaz‐Gómez, José L. , Díaz-Gómez, José L

Mayo Clinic

International Anesthesiology Clinics | March 13, 2019 | Volume: 57 | Issue: 2 | Pages: 75-88

10.1097/aia.0000000000000225 | PMID 30864992 Get It

Clinical evaluation of germline polymorphisms (SNPs) associated with capecitabine (C) toxicity (tox) in metastatic breast cancer (MBC).
O’Donnell, Peter H. , Nurhussein-Patterson, Ashley, Huo, Dezheng , Morrow, Phuong K. , Storniolo, Anna Maria , Forero‐Torres, Andres , Poznak, Catherine Van , Merkel, Douglas E., Rosner, Gary L. , Ratain, Mark J. , Dolan, M. Eileen , Nanda, Rita , Trubetskoy, Vassily Vladimirovich , Hall, Julianne P. , Fleming, Gini F. , Ingle, James N. , Mayer, Ingrid A. , Olopade, Olufunmilayo I. , Cox, Nancy J.

Mayo Clinic

Journal of Clinical Oncology | March 7, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 1049-1049

10.1200/jco.2015.33.15_suppl.1049 Get It